BTAIQ — BioXcel Therapeutics Share News
0.000.00%
Last trade - 00:00- $0.53m
- $92.14m
- $0.64m
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna
Brief: Bioxcel Therapeutics Enters Into Asset Sale Agreement With Teva Pharmaceuticals
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna, Ulta Beauty
Brief: Bioxcel Therapeutics Says Deal With Teva Includes $57.5 Mln Cash, Up To $67.5 Mln Development Milestones
BioXcel falls after filing for Chapter 11 bankruptcy
Biopharma firm BioXcel Therapeutics files for bankruptcy in US
Brief: Bioxcel Therapeutics Enters Fourteenth Amendment To Credit Agreement On August 24, 2026
BioXcel Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: BioXcel Therapeutics Enters Twelfth Amendment To Credit Agreement On August 10, 2026 - SEC Filing
BioXcel Therapeutics Inc expected to post a loss of 51 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Meta, Legence, Chegg
U.S. STOCKS ON THE MOVE-Hims & Hers, Chewy, Longeveron
U.S. STOCKS ON THE MOVE-Delta, Levi's, banks
Brief: BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
U.S. STOCKS ON THE MOVE-Delta, GATX, Humana
BioXcel rises as trial starts for its stress disorder drug in trauma victims
AI-driven biopharma firm BioXcel Therapeutics posts lower-than-expected Q4 loss on reduced SG&A costs
Brief: BioXcel Therapeutics Q4 Basic EPS USD -0.58 Vs. IBES Estimate USD -0.75